Chengdu Second People's Hospital, Chengdu, China.
Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Complement Ther Clin Pract. 2022 Nov;49:101625. doi: 10.1016/j.ctcp.2022.101625. Epub 2022 Jun 30.
Studies in animals and humans have reported numerous beneficial effects of cinnamon. However, its hypolipidemic efficacy in patients with metabolic syndrome (MetS) and related disorders is still controversial. This meta-analysis aimed to evaluate the lipid-regulating effects and safety of cinnamon in a population with MetS and related disorders.
Studies that met the inclusion criteria were retrieved from PubMed, Embase, Cochrane Library, and Web of Science. Randomized placebo-controlled trials of cinnamon or its extracts in the treatment of MetS and related metabolic diseases were the main eligibility criteria. The Cochrane Handbook was used to guide the study selection, quality assessment, and data analysis. All statistical analyses were performed using Stata 15.0.
Twelve studies involving 773 subjects were included in the meta-analysis. The overall results showed that cinnamon could significantly reduce total cholesterol (weighted mean difference [WMD]: -0.19 mmol/L [-7.34 mg/dL]; 95% confidence interval [CI]: -0.24, -0.14 [-9.27, -5.41]), triglyceride (WMD: -0.10 mmol/L [-8.85 mg/dL]; 95% CI: -0.16, -0.04 [-14.16, -3.54]), and low-density lipoprotein cholesterol (WMD: -0.16 mmol/L [-6.18 mg/dL]; 95% CI: -0.20, -0.11 [-7.72, -4.25]). In the subgroup analysis, cinnamon did not exhibit a significant effect on lipid profiles in European and American patients. Larger doses of cinnamon tended to exhibit better regulation of lipid profiles and high-dose cinnamon (≥1.5 g/d) significantly increased high-density lipoprotein cholesterol (WMD: 0.07 mmol/L [2.70 mg/dL]; 95% CI: 0.03, 0.11 [1.16, 4.25]).
The current evidence shows that cinnamon can regulate lipid profiles in patients with metabolic disorders.
动物和人类研究报告称，肉桂有许多有益的作用。然而，肉桂对代谢综合征（MetS）和相关疾病患者的降血脂疗效仍存在争议。本荟萃分析旨在评估肉桂对 MetS 及相关疾病患者的调脂作用和安全性。
从 PubMed、Embase、Cochrane 图书馆和 Web of Science 检索符合纳入标准的研究。肉桂或其提取物治疗 MetS 和相关代谢性疾病的随机安慰剂对照试验是主要纳入标准。采用 Cochrane 手册指导研究选择、质量评估和数据分析。所有统计分析均使用 Stata 15.0 进行。
荟萃分析纳入了 12 项涉及 773 例患者的研究。总体结果表明，肉桂可显著降低总胆固醇（加权均数差 [WMD]：-0.19mmol/L [-7.34mg/dL]；95%置信区间 [CI]：-0.24，-0.14 [-9.27，-5.41]）、三酰甘油（WMD：-0.10mmol/L [-8.85mg/dL]；95% CI：-0.16，-0.04 [-14.16，-3.54]）和低密度脂蛋白胆固醇（WMD：-0.16mmol/L [-6.18mg/dL]；95% CI：-0.20，-0.11 [-7.72，-4.25]）。亚组分析显示，肉桂对欧美患者的血脂谱无显著影响。肉桂剂量越大，调脂效果越好，高剂量肉桂（≥1.5g/d）可显著升高高密度脂蛋白胆固醇（WMD：0.07mmol/L [2.70mg/dL]；95% CI：0.03，0.11 [1.16，4.25]）。
现有证据表明，肉桂可调节代谢紊乱患者的血脂谱。
